You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Moodys
Baxter
Dow
Boehringer Ingelheim

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Patent: 8,828,401

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,828,401
Title:Cytotoxic peptides and antibody drug conjugates thereof
Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
Inventor(s): Doroski; Matthew David (Mystic, CT), Maderna; Andreas (Stony Point, NY), O\'Donnell; Christopher John (Mystic, CT), Subramanyam; Chakrapani (South Glastonburty, CT), Vetelino; Beth (North Stonington, CT), Dushin; Russell George (Old Lyme, CT), Strop; Pavel (San Mateo, CA), Graziani; Edmund Idris (Chestnut Ridge, NY)
Assignee: Pfizer Inc. (New York, NY)
Application Number:13/670,612
Patent Claims:see list of patent claims

Details for Patent 8,828,401

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Pfizer Inc. (New York, NY) 2031-11-17 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Pfizer Inc. (New York, NY) 2031-11-17 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Pfizer Inc. (New York, NY) 2031-11-17 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Pfizer Inc. (New York, NY) 2031-11-17 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Medtronic
Merck
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.